medigraphic.com
ISSN 1561-3186 (Electronic)

2021, Number 1

<< Back Next >>

Rev Acta Médica 2021; 22 (1)

Orbital lymphoma of mantle cell treated with chemotherapy

Cáceres TO, Cáceres TM, Roche AC, Vicente GJA, Zhao R

Language: Spanish
References: 18
Page:
PDF size: 154.71 Kb.


ABSTRACT

Introduction: Lymphomas are solid lymphoid cell tumors. They are subdivided into Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL). The case to be treated is a type of NHL located in the ocular orbit of a patient. Its incidence in the population increases with age, which makes it possible to appear even at ages over 80 years.
Case presentation: The case is presented of a 73-year-old female patient with bilateral exophthalmos. A clinical ocular and systemic examination is performed. Imaging studies show the tumor in both orbits, larger on the right. The initial diagnosis was inflammatory pseudotumor of the orbit, confirmed by a first biopsy. Due to the lack of clinical improvement with steroids, biopsy was repeated. On this occasion, half of the left orbital mass was taken. According to the studies carried out by the pathologist, it is a mantle cell lymphoma (MCL), secondary to the orbit, with a high degree of malignancy. The histological test for cyclin was crucial for the positive and differential diagnosis.
Results: Chemotherapy treatment was decided with the CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) therapeutic scheme. The outcomes were satisfactory, with a current survival of one year of evolution.


REFERENCES

  1. Correa Negrete LG, Melero M, Avagnina A. Masa orbitaria como forma de presentación de Leucemia/Linfoma Linfoblástico B. Hematología. 2013[acceso:11/4/2020];17(1):86-88. Disponible en: http://www.sah.org.ar/Revista/resumen.asp?id=5092

  2. Pizarro Barrera M, Corredor Casas S, Salcedo Casillas G, Rodríguez Reyes A. Linfoma orbitario: reporte de un caso. Rev Mex Oftalmol. 2006[acceso:11/4/2020];80(2):89-92. Disponible en. https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=17133

  3. Khosravi Shahi P, Del Castillo Ruedas A, Pérez Manga G. Linfoma del manto. An Med Interna. 2007[acceso:11/4/2020];24:142-5. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212- 71992007000300010

  4. Balagué O, Colomo L, Campo E. Linfoma de células del manto. REV ESP PATOL. 2004[acceso:11/4/2020];37(2):159-72. Disponible en. https://pesquisa.bvsalud.org/portal/resource/pt/ibc-37535

  5. Karlin J, Peck T, Prenshaw K, Portell CA, Kirzhner M. Orbital mantle cell lymphoma presenting as myasthenia gravis. Orbit. 2017;36(6):365-9. Pubmed:PMID:28820310

  6. Olsen TG, Heegaard S. Orbital lymphoma. Surv Ophthalmol. 2019;64(1):45- 66. PubMed: PMID:30144455.

  7. Di Nisioa L, Zárateb J, Weila D. Linfomas orbitarios. Oftalmol Clin Exp. 2017[acceso:11/4/2020];10(3). Disponible en: https://www.elsevier.es/esrevista- revista-mexicana-oftalmologia-321

  8. Briscoe D, Safieh C, Ton Y, Shapiro H, Assia E, Kidron D. Characteristics of orbital lymphoma: a clinicopathological study of 26 cases. Int Ophthalmol. 2018;38:271-7. DOI: https://doi.org/10.1007/s10792-017-0457-y

  9. Verma S, Gupta N, Mohindra S, Sachdeva MS, Rajwanshi A. Primary orbital mantle cell lymphoma: Flow cytometric immunophenotyping as an adjunct to fine-needle aspiration cytology for diagnosis. Cyto Journal. 2017;14:2. DOI: https://doi.org/10.4103/1742-6413.198816

  10. Sachanas S, Gerassimos D, Pangalis T. Combination of Rituximab- Clorambucil as firs line treatment in patients with mantle cell lymphoma:highly effective regimen. Leuk-Lymph. 2011;52;3:387-9. DOI: https://www.tandfonline.com/doi/abs/10.3109/10428194.2010.534518

  11. Rummel MJ, Niederle N, Maschmeyer G. Bendamustine plus rituximab (BR) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. J Clin Oncol. 2012[acceso:11/4/2020];30:3-6. Disponible en: https://www.researchgate.net/publication/225085077

  12. Albano D, Laudicella R, Ferro P, Allocca M, Abenavoli E, Buschiazzo. et al. The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study. Cancers. 2019;11(12):183. DOI: https://doi.org/10.3390/cancers11121831

  13. Iqbal M, Castano Y, Mohamed A T, Dabaja K. intraocular involvement of Mantle cell lymphoma: A case report and literature review. Hematol Oncol Stem Cell. 2019;3:1658-66. DOI: https://doi.org/10.1016/j.hemonc.2019.03.002 1658-76

  14. Koban Y, Özlece H, Ayar O, Koç M, Çelik H, Yazar Z et al. Mantle Cell Lymphoma Presenting with Acute Bilateral Ophthalmoplegia. Turk J Ophthalmol. 2017[acceso:11/4/2020];47:235-7. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563554/

  15. Rasíc D, Knezevic M, Tercíc T, Vlajkovíc G. Bilateral ocular panadnexal mass of initial presentation of systemic blastoid variant of mantle-cell lymphoma. Survey of ophthalmology. 2017;62:83-8 Disponible en: https://pubmed.ncbi.nlm.nih.gov/19429588/

  16. Knudsen MKH, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, et al. Clinicopathological features of ocular adnexal mantle-cell lymphoma in an international multicenter cohort. JAMA Ophthalmol. 2017;135(12):1367-74. PubMed.PMID:29121219

  17. Hemadymes W. Karesh, John C. Baer K, Ramzi KH. Noninfectious orbital inflammatory disease. En Duane’s Ophthalmology on CD-ROM. Tasman E, Jaeger E (ed). Version 2. Lippincott Williams and Wilking; 2006.

  18. Perdomo F, Saborit Y, Ortiz D, Jiménez J. Características clínicopatológicas y tratamiento del linfoma orbitario. Revista Cubana de Oftalmología. 2019[acceso:11/4/2020];32(4). Disponible en: http://www.revoftalmologia.sld.cu/index.php/oftalmologia/article/view/809/html_434




2020     |     www.medigraphic.com